Matt Miksic
Stock Analyst at Barclays
(3.86)
# 623
Out of 4,862 analysts
282
Total ratings
60.89%
Success rate
4.69%
Average return
Main Sectors:
Stocks Rated by Matt Miksic
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLCO Bausch + Lomb | Maintains: Equal-Weight | $19 → $16 | $12.33 | +29.76% | 5 | Jun 9, 2025 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $261 → $241 | $172.21 | +39.95% | 1 | Jun 3, 2025 | |
| LIVN LivaNova | Maintains: Equal-Weight | $56 → $55 | $45.70 | +20.35% | 7 | May 8, 2025 | |
| OBIO Orchestra BioMed Holdings | Maintains: Overweight | $16 → $12 | $3.09 | +288.35% | 2 | May 5, 2025 | |
| DXCM DexCom | Maintains: Equal-Weight | $90 → $93 | $81.99 | +13.43% | 6 | May 5, 2025 | |
| PODD Insulet | Maintains: Equal-Weight | $234 → $266 | $304.63 | -12.68% | 8 | Apr 30, 2025 | |
| INMD InMode | Maintains: Overweight | $29 → $24 | $13.36 | +79.64% | 13 | Apr 30, 2025 | |
| BSX Boston Scientific | Maintains: Overweight | $118 → $125 | $99.74 | +25.33% | 17 | Apr 25, 2025 | |
| ISRG Intuitive Surgical | Maintains: Overweight | $684 → $635 | $512.18 | +23.98% | 7 | Apr 24, 2025 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $166 → $165 | $157.10 | +5.03% | 12 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $158 → $159 | $135.62 | +17.24% | 29 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $41 | $30.62 | +33.90% | 21 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $53 | $20.77 | +155.24% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $103 | $58.90 | +74.87% | 15 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $88 → $90 | $75.15 | +19.76% | 28 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $118 → $112 | $91.28 | +22.70% | 7 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $418 → $443 | $377.30 | +17.41% | 23 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $11.06 | +89.96% | 2 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $4.38 | +402.28% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $109 | $87.27 | +24.90% | 21 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $16 | $9.10 | +75.82% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $96 | $86.20 | +11.37% | 9 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $100 | $70.19 | +42.47% | 8 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $722 → $418 | $177.85 | +135.03% | 3 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $28 | $11.43 | +144.97% | 2 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $67 | $15.62 | +328.94% | 1 | Mar 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $480 | $7.92 | +5,960.61% | 1 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $87 | $12.16 | +615.46% | 14 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $3.07 | +714.33% | 5 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $9 | $6.04 | +49.01% | 1 | Dec 12, 2016 |
Bausch + Lomb
Jun 9, 2025
Maintains: Equal-Weight
Price Target: $19 → $16
Current: $12.33
Upside: +29.76%
Becton, Dickinson and Company
Jun 3, 2025
Maintains: Overweight
Price Target: $261 → $241
Current: $172.21
Upside: +39.95%
LivaNova
May 8, 2025
Maintains: Equal-Weight
Price Target: $56 → $55
Current: $45.70
Upside: +20.35%
Orchestra BioMed Holdings
May 5, 2025
Maintains: Overweight
Price Target: $16 → $12
Current: $3.09
Upside: +288.35%
DexCom
May 5, 2025
Maintains: Equal-Weight
Price Target: $90 → $93
Current: $81.99
Upside: +13.43%
Insulet
Apr 30, 2025
Maintains: Equal-Weight
Price Target: $234 → $266
Current: $304.63
Upside: -12.68%
InMode
Apr 30, 2025
Maintains: Overweight
Price Target: $29 → $24
Current: $13.36
Upside: +79.64%
Boston Scientific
Apr 25, 2025
Maintains: Overweight
Price Target: $118 → $125
Current: $99.74
Upside: +25.33%
Intuitive Surgical
Apr 24, 2025
Maintains: Overweight
Price Target: $684 → $635
Current: $512.18
Upside: +23.98%
Johnson & Johnson
Apr 17, 2025
Maintains: Equal-Weight
Price Target: $166 → $165
Current: $157.10
Upside: +5.03%
Apr 17, 2025
Maintains: Overweight
Price Target: $158 → $159
Current: $135.62
Upside: +17.24%
Mar 10, 2025
Maintains: Overweight
Price Target: $39 → $41
Current: $30.62
Upside: +33.90%
Feb 28, 2025
Maintains: Overweight
Price Target: $60 → $53
Current: $20.77
Upside: +155.24%
Feb 24, 2025
Maintains: Overweight
Price Target: $100 → $103
Current: $58.90
Upside: +74.87%
Feb 13, 2025
Maintains: Overweight
Price Target: $88 → $90
Current: $75.15
Upside: +19.76%
Feb 10, 2025
Maintains: Underweight
Price Target: $118 → $112
Current: $91.28
Upside: +22.70%
Feb 10, 2025
Maintains: Overweight
Price Target: $418 → $443
Current: $377.30
Upside: +17.41%
Jan 22, 2025
Maintains: Overweight
Price Target: $20 → $21
Current: $11.06
Upside: +89.96%
Jan 7, 2025
Initiates: Overweight
Price Target: $22
Current: $4.38
Upside: +402.28%
Nov 26, 2024
Maintains: Overweight
Price Target: $105 → $109
Current: $87.27
Upside: +24.90%
Mar 5, 2024
Maintains: Underweight
Price Target: $13 → $16
Current: $9.10
Upside: +75.82%
May 13, 2022
Assumes: Outperform
Price Target: $96
Current: $86.20
Upside: +11.37%
May 13, 2022
Assumes: Outperform
Price Target: $100
Current: $70.19
Upside: +42.47%
May 4, 2022
Maintains: Outperform
Price Target: $722 → $418
Current: $177.85
Upside: +135.03%
Mar 2, 2022
Maintains: Outperform
Price Target: $31 → $28
Current: $11.43
Upside: +144.97%
Mar 1, 2022
Maintains: Outperform
Price Target: $68 → $67
Current: $15.62
Upside: +328.94%
Jan 7, 2022
Initiates: Outperform
Price Target: $480
Current: $7.92
Upside: +5,960.61%
Nov 3, 2021
Maintains: Outperform
Price Target: $84 → $87
Current: $12.16
Upside: +615.46%
Aug 10, 2021
Maintains: Outperform
Price Target: $24 → $25
Current: $3.07
Upside: +714.33%
Dec 12, 2016
Initiates: Sell
Price Target: $9
Current: $6.04
Upside: +49.01%